Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb – Research Grade

Introduction to Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb

Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Tigatuzumab. This biosimilar targets the tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), also known as CD262, which is a cell surface receptor involved in cell death and survival pathways. In this article, we will explore the structure, activity, and potential applications of Tigatuzumab Biosimilar.

Structure of Tigatuzumab Biosimilar

Tigatuzumab Biosimilar is a monoclonal antibody, which means it is a type of protein that is produced by a single clone of cells. It is designed to mimic the structure and function of the original therapeutic antibody, Tigatuzumab. The biosimilar is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. These chains are further divided into variable and constant regions. The variable regions are responsible for binding to the target, while the constant regions determine the effector functions of the antibody.

Activity of Tigatuzumab Biosimilar

Tigatuzumab Biosimilar specifically targets TNFRSF10B, a cell surface receptor that is overexpressed in many types of cancer. This receptor is involved in the regulation of cell death and survival pathways, making it an attractive therapeutic target for cancer treatment. By binding to TNFRSF10B, Tigatuzumab Biosimilar blocks its interaction with its ligands, which leads to the activation of cell death pathways and ultimately results in the death of cancer cells.

In addition to its direct anti-tumor activity, Tigatuzumab Biosimilar also has immune-modulating effects. It can activate immune cells, such as natural killer cells and macrophages, to further enhance the destruction of cancer cells. This dual mechanism of action makes Tigatuzumab Biosimilar a promising candidate for cancer therapy.

Applications of Tigatuzumab Biosimilar

Tigatuzumab Biosimilar is currently being evaluated in preclinical and clinical studies for its potential use in the treatment of various types of cancer. It has shown promising results in early-phase clinical trials for the treatment of multiple myeloma, a type of blood cancer, as well as solid tumors, such as lung cancer and pancreatic cancer.

The biosimilar is also being investigated for its potential use in combination with other anti- cancer therapies, such as chemotherapy and radiation therapy. Combining Tigatuzumab Biosimilar with these treatments may enhance their efficacy and reduce the risk of resistance development.

Conclusion

In summary, Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb is a monoclonal antibody that targets the TNFRSF10B receptor, involved in cell death and survival pathways. Its structure mimics that of the original therapeutic antibody, Tigatuzumab, and it has both direct anti-tumor and immune-modulating effects. This biosimilar is currently being studied for its potential use in the treatment of various types of cancer, either as a standalone therapy or in combination with other treatments. Further research and clinical trials are needed to fully evaluate the efficacy and safety of Tigatuzumab Biosimilar, but it holds great promise as a potential anti- cancer therapy.